Skip to main content
PMC home page
Trials logoLink to Trials
. 2020 Jul 19;21:660. doi: 10.1186/s13063-020-04608-4

Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

Grazia Daniela Femminella 1,#, Eleni Frangou 2,#, Sharon B Love 2, Gail Busza 1, Clive Holmes 3, Craig Ritchie 1, Robert Lawrence 4, Brady McFarlane 3, George Tadros 5, Basil H Ridha 6, Carol Bannister 7, Zuzana Walker 8, Hilary Archer 9, Elizabeth Coulthard 9, Ben R Underwood 10, Aparna Prasanna 11, Paul Koranteng 12, Salman Karim 13, Kehinde Junaid 14, Bernadette McGuinness 15, Ramin Nilforooshan 16, Ajay Macharouthu 17, Andrew Donaldson 18, Simon Thacker 19, Gregor Russell 20, Naghma Malik 21, Vandana Mate 22, Lucy Knight 23, Sajeev Kshemendran 24, John Harrison 25,26, Christian Hölscher 27, David J Brooks 1,28, Anthony Peter Passmore 15, Clive Ballard 7, Paul Edison 1,29,✉
PMCID: PMC7370449  PMID: 32684162

Correction to: Trials (2019) 20: 191

https://doi.org/10.1186/s13063-019-3259-x

After publication of our article [1] the authors have notified us that the name of Prof. Christian Hölscher had been inadvertently forgotten when compiling the list of authors. Dr. Hölscher developed the concept of testing liraglutide in Alzheimer’s mouse model, has done the preclinical experiments, and is a co-applicant of the Alzheimer Society UK grant that partially funds the study.

Footnotes

Grazia Daniela Femminella and Eleni Frangou contributed equally to this work.

Reference

  • 1.Femminella, et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study) Trials. 2019;20:191. doi: 10.1186/s13063-019-3259-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Trials are provided here courtesy of BMC

RESOURCES